Categories: Health

Transactions in connection with share buy-back program

Company announcement no. 10 – 26
14 April 2026

Transactions in connection with share buy-back program

On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 – 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules.

The purposes of the share buy-back programme are to meet obligations relating to acquisition of minority shareholders’ shares in NTG subsidiaries under the “Ring-the-Bell” concept, cover obligations arising under share-based incentive programmes, and potentially for other purposes such as payment in relation to potential M&A transactions.

During the period, NTG will purchase its own shares for an aggregate maximum amount of DKK 200,000,000, up to 1,250,000 shares (nominally DKK 25,000,000), corresponding to 5.52% of the current share capital of NTG.

The share buy-back programme will run from 5 March 2026 to 9 November 2026 at the latest, both days inclusive.

The following transactions have been made under the share buy-back program:

  Number of shares Average purchase price (DKK) Transaction value (DKK)
Accumulated, latest announcement 154,870   25,409,420
07 April 2026 12,503 171.7 2,146,933
08 April 2026 1,827 180.1 328,959
09 April 2026 1,128 179.5 202,481
10 April 2026 1,600 186.6 298,560
13 April 2026 2,452 184.2 451,768
Accumulated under the program 174,380   28,838,121

With the transactions stated above, NTG owns a total of 595,784 treasury shares, corresponding to 2.63% of the current share capital of NTG.

Details of each transaction are included as appendix.

Additional information

For additional information, please contact:

GlobeNews Wire

Recent Posts

Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf…

20 minutes ago

Making Waves Across Borders: Manipal Hospitals Presents the First-Ever Sri Lanka-India Open Water Swim by a Couple

BENGALURU, India, May 4, 2026 /PRNewswire/ -- Manipal Hospitals, India's largest pan-India multispecialty hospital network by…

20 minutes ago

G-P Positioned as the Leader in the SPARK Matrix: Employer of Record (EOR) Solutions, 2026 by QKS Group

G-P achieves the highest position among all vendors with strong ratings in technology excellence and…

3 hours ago

SINGAPORE INTERNATIONAL FESTIVAL OF ARTS 2026 SETS THE STAGE FOR “LET’S PLAY!”

SINGAPORE, May 4, 2026 /PRNewswire/ -- Organised by Arts House Group, Singapore International Festival of Arts…

3 hours ago

Signing Deals with 10 Countries! WALOVI Global Partner Conference Held in Guangzhou

GUANGZHOU, China, May 4, 2026 /PRNewswire/ -- On May 2, 2026, during the 139th Canton…

4 hours ago

MEDIA ALERT: IBM CEO ARVIND KRISHNA TO OPEN IBM THINK 2026, OUTLINING HOW AI AND QUANTUM WILL DEFINE THE ENTERPRISE

BOSTON, May 4, 2026 /PRNewswire/ -- Tune in live Tuesday, May 5 at 8:30 a.m.…

4 hours ago